Indian regulators have turned their attention to pay-for-delay agreements, making the nation the latest to scrutinize such agreements that have particular impact on the pharmaceutical industry.
According to reports, the Competition Commission of India is examining patent settlements made between foreign brand-name pharmaceutical companies and their generic counterparts in India. Reports say the probe is in response to concerns that some of those settlements may lead to cheaper, generic drugs being unavailable to consumers.
Reports say at least two patent settlements are being investigated by the CCI. One of which involves Roche’s lung cancer drug and an agreement the pharma giant made with generic drug maker Cipla. The other, reports say, involves Glenmark Pharmaceuticals, one of India’s largest generic companies, and an agreement with Merck over a diabetes drug.
Officials noted that the agreements will be probed on a case-by-case basis to determine if they resulted in anticompetitive effects.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UFC Reaches $375 Million Settlement in Antitrust Case
Feb 6, 2025 by
CPI
Brazilian Architecture Council Convicted of Antitrust Violations
Feb 6, 2025 by
CPI
Bipartisan Bill Seeks to Ban Chinese AI Software from US Government Devices
Feb 6, 2025 by
CPI
Senators Call for Investigation into RealPage Algorithm’s Impact on Military Housing Costs
Feb 6, 2025 by
CPI
ECB Seeks Faster Digital Euro Legislation Amid US Stablecoin Push
Feb 6, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon